Stock Track | TG Therapeutics Soars 15.91% Intraday on Raised Revenue Guidance and Strong Q1 Results

Stock Track05-07

TG Therapeutics' stock soared 15.91% during intraday trading on Wednesday, driven by the company's upbeat first-quarter financial performance and raised full-year revenue outlook.

The biopharmaceutical company reported first-quarter revenue of approximately $205 million, a significant increase from $120.9 million a year earlier, with net income rising to $19.8 million from $5.1 million. The growth was primarily fueled by strong demand for its multiple sclerosis drug BRIUMVI.

Furthermore, TG Therapeutics raised its 2026 total global revenue target to about $925 million and increased its BRIUMVI U.S. net product revenue guidance to $885-$900 million. Additionally, analyst firm H.C. Wainwright raised its price target on the stock to $70 from $60, maintaining a Buy rating, contributing to positive investor sentiment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1169464560?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-07 02:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169464560","market":"sg","top_or_hot":-1,"title":"Stock Track | TG Therapeutics Soars 15.91% Intraday on Raised Revenue Guidance and Strong Q1 Results","media":"Stock Track","content":"<p>TG Therapeutics' stock soared 15.91% during intraday trading on Wednesday, driven by the company's upbeat first-quarter financial performance and raised full-year revenue outlook.</p><p>The biopharmaceutical company reported first-quarter revenue of approximately $205 million, a significant increase from $120.9 million a year earlier, with net income rising to $19.8 million from $5.1 million. The growth was primarily fueled by strong demand for its multiple sclerosis drug BRIUMVI.</p><p>Furthermore, TG Therapeutics raised its 2026 total global revenue target to about $925 million and increased its BRIUMVI U.S. net product revenue guidance to $885-$900 million. Additionally, analyst firm H.C. Wainwright raised its price target on the stock to $70 from $60, maintaining a Buy rating, contributing to positive investor sentiment.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | TG Therapeutics Soars 15.91% Intraday on Raised Revenue Guidance and Strong Q1 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | TG Therapeutics Soars 15.91% Intraday on Raised Revenue Guidance and Strong Q1 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-07 02:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TG Therapeutics' stock soared 15.91% during intraday trading on Wednesday, driven by the company's upbeat first-quarter financial performance and raised full-year revenue outlook.</p><p>The biopharmaceutical company reported first-quarter revenue of approximately $205 million, a significant increase from $120.9 million a year earlier, with net income rising to $19.8 million from $5.1 million. The growth was primarily fueled by strong demand for its multiple sclerosis drug BRIUMVI.</p><p>Furthermore, TG Therapeutics raised its 2026 total global revenue target to about $925 million and increased its BRIUMVI U.S. net product revenue guidance to $885-$900 million. Additionally, analyst firm H.C. Wainwright raised its price target on the stock to $70 from $60, maintaining a Buy rating, contributing to positive investor sentiment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TGTX","symbol_name":"TG Therapeutics Inc.","start_time":0,"source_url":"","article_id":"1169464560","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169464560","pubTimestamp":1778093687,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"TG Therapeutics' stock soared 15.91% during intraday trading on Wednesday, driven by the company's upbeat first-quarter financial performance and raised full-year revenue outlook.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TGTX":"TG Therapeutics Inc."},"translate_title":"个股追踪|TG Therapeutics盘中大涨15.91%营收指引上调Q1业绩强劲","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TGTX":1},"content_text":"TG Therapeutics' stock soared 15.91% during intraday trading on Wednesday, driven by the company's upbeat first-quarter financial performance and raised full-year revenue outlook.The biopharmaceutical company reported first-quarter revenue of approximately $205 million, a significant increase from $120.9 million a year earlier, with net income rising to $19.8 million from $5.1 million. The growth was primarily fueled by strong demand for its multiple sclerosis drug BRIUMVI.Furthermore, TG Therapeutics raised its 2026 total global revenue target to about $925 million and increased its BRIUMVI U.S. net product revenue guidance to $885-$900 million. Additionally, analyst firm H.C. Wainwright raised its price target on the stock to $70 from $60, maintaining a Buy rating, contributing to positive investor sentiment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1169464560","isCrawlerRequest":true}